Authors: Jade Parker, Editor
Moffitt Cancer Center (FL, USA) researchers have discovered that desmoplastic melanoma patients are more responsive to anti-PD-1/PD-L1 therapies than previously assumed; the findings were published recently in Nature.
Desmoplastic melanoma is characterized by a dense fibrous stroma, resistance to chemotherapy and a lack of actionable driver mutations. It was previously believed that the tissue architecture of desmoplastic melanomas would reduce the ability of immune cells to infiltrate the tumor area and limit the effectiveness of immune-activating drugs.
- Discover a patients perspective of this news in this blog from Stage IV melanoma patient T.J. Sharpe
In this study, researchers analyzed 60 patients with advanced desmoplastic melanoma who had previously been treated with antibodies to block PD-1/PD-L1. They discovered that